Wreghitt T G, Gandhi M K, Gray J J, Blagdon J, Rankin A, Coates P B
Clinical Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Cambridge.
Clin Lab Haematol. 1993;15(2):141-4. doi: 10.1111/j.1365-2257.1993.tb00138.x.
The Blood Transfusion Service introduced screening for Hepatitis C antibody (HCV) in September 1991. This is done by second generation enzyme linked immunosorbent assay (ELISA) tests. We present a case of post-transfusion hepatitis C hepatitis in a patient with myeloma. Infection was acquired before screening was introduced. Both the patient and the infected blood donor were diagnosed using ELISA assays and the polymerase chain reaction (PCR). In this way we prevented the blood donor from spreading the virus via subsequent blood donations. There were some interesting discrepancies in the HCV assays. Blood samples, when tested by different methods, gave both positive and negative results. The results also varied according to when the blood samples to be tested were taken. The case illustrates the importance of confirming positive results and that no single laboratory test is entirely satisfactory in diagnosing HCV infection.
输血服务机构于1991年9月开始对丙型肝炎抗体(HCV)进行筛查。这是通过第二代酶联免疫吸附测定(ELISA)检测来完成的。我们报告一例骨髓瘤患者输血后丙型肝炎病例。感染发生在筛查引入之前。患者和受感染的献血者均通过ELISA检测和聚合酶链反应(PCR)进行诊断。通过这种方式,我们防止了该献血者通过后续献血传播病毒。在HCV检测中存在一些有趣的差异。血液样本用不同方法检测时,结果有阳性也有阴性。结果还根据待检测血液样本的采集时间而有所不同。该病例说明了确认阳性结果的重要性,以及在诊断HCV感染方面没有单一的实验室检测是完全令人满意的。